ArticleEuropean journal of medical research2025
MYBL2 regulates the expression of CENPF in lung adenocarcinoma and promotes tumor development and metastasis through AKT pathway activation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLung adenocarcinoma (LUAD) is a major global health burden with high mortality. Elevated expression of MYBL2 and CENPF is correlated with unfavorable clinical outcomes in LUAD. However, the relationship between MYBL2 and CENPF and the downstream signaling pathways of MYBL2 and CENPF in LUAD remains elusive.
methodsWe investigated MYBL2 and CENPF expression in TCGA data and clinical LUAD samples, identifying a significant correlation. Functional studies in A549 cells demonstrated that MYBL2 acts upstream of CENPF, promoting tumor proliferation and migration. This oncogenic effect was mediated through AKT signaling, as AKT inhibition phenocopied the suppressive effects of CENPF knockdown.
resultsAnalysis of TCGA data and clinical specimens confirmed significant upregulation of MYBL2 and CENPF in LUAD compared to normal tissues. Their expression correlated positively with advanced disease stage and poorer prognosis across diverse patient subgroups. Functional studies demonstrated that MYBL2 acts upstream of CENPF, as its overexpression elevated CENPF levels, while its knockdown reduced them. CENPF depletion markedly attenuated LUAD cell proliferation and migration. Mechanistically, both MYBL2 overexpression and CENPF knockdown modulated AKT pathway activation, as evidenced by altered phosphorylation levels. Accordingly, pharmacological inhibition of AKT with GDC-0068 recapitulated the anti-tumor effects observed with CENPF knockdown.
conclusionsThe expression of MYBL2 and CENPF in lung adenocarcinoma increases with LUAD progression. MYBL2 regulates the expression of CENPF in LUAD, and the elevated CENPF promotes the proliferation and migration of LUAD cells. Both MYBL2 and CENPF regulate the proliferation and migration of LUAD through AKT pathway activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.